Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference

   Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference

PR Newswire

NEWARK, Calif., June 11, 2013

NEWARK, Calif., June 11, 2013 /PRNewswire/ --Depomed, Inc. (NASDAQ:DEPO)
today announced that it will be presenting at the Wells Fargo Securities 2013
Healthcare Conference at the Intercontinental Hotel in Boston, MA.

The presentation at the Wells Fargo conference is scheduled for 11:15 am EDT
(8:15 am PDT) on Wednesday, June 19, 2013. The presentation will be webcast,
and the webcast can be accessed via the Investor Relations page of the Depomed
website at www.depomed.com. A recording of the webcast will be archived for
30 days on the company's website.

About Depomed
Depomed, Inc.is a specialty pharmaceutical company with three approved and
marketed products. Gralise^®(gabapentin) is a once-daily treatment approved
for the management of postherpetic neuralgia (PHN). Zipsor^®(diclofenac
potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug
(NSAID) indicated for relief of mild to moderate acute pain in adults.
Glumetza^® (metformin hydrochloride extended release tablets) is approved for
use in adults with type 2 diabetes and is commercialized bySantarus,
Inc.inthe United States. The company formulates its products and product
candidates with its proven, proprietary Acuform^®drug delivery technology,
which is designed to improve existing oral medications, allowing for extended
release of medications to the upper gastrointestinal tract when dosed with
food. Additional information aboutDepomedmay be found on its
website,www.depomed.com.

CONTACT: August J. Moretti
Depomed, Inc. 510.744.8000
amoretti@depomed.com

SOURCE Depomed, Inc.

Website: http://www.depomed.com